Cryopreserved cGMP-compliant human pluripotent stem cell-derived hepatic progenitors rescue mice from acute liver failure through rapid paracrine effects on liver cells.
Acetaminophen
Acute liver failure
Cryopreservation
Hepatic progenitor cells
Pluripotent stem cells
Regenerative medicine
Thioacetamide
cGMP
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
12 Mar 2024
12 Mar 2024
Historique:
received:
10
11
2023
accepted:
20
02
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
epublish
Résumé
Liver transplantation remains the only curative treatment for end-stage liver diseases. Unfortunately, there is a drastic organ donor shortage. Hepatocyte transplantation emerged as a viable alternative to liver transplantation. Considering their unique expansion capabilities and their potency to be driven toward a chosen cell fate, pluripotent stem cells are extensively studied as an unlimited cell source of hepatocytes for cell therapy. It has been previously shown that freshly prepared hepatocyte-like cells can cure mice from acute and chronic liver failure and restore liver function. Human PSC-derived immature hepatic progenitors (GStemHep) were generated using a new protocol with current good manufacturing practice compliant conditions from PSC amplification and hepatic differentiation to cell cryopreservation. The therapeutic potential of these cryopreserved cells was assessed in two clinically relevant models of acute liver failure, and the mode of action was studied by several analytical methods, including unbiased proteomic analyses. GStemHep cells present an immature hepatic phenotype (alpha-fetoprotein positive, albumin negative), secrete hepatocyte growth factor and do not express major histocompatibility complex. A single dose of thawed GStemHep rescue mice from sudden death caused by acetaminophen and thioacetamide-induced acute liver failure, both in immunodeficient and immunocompetent animals in the absence of immunosuppression. Therapeutic biological effects were observed as soon as 3 h post-cell transplantation with a reduction in serum transaminases and in liver necrosis. The swiftness of the therapeutic effect suggests a paracrine mechanism of action of GStemHep leading to a rapid reduction of inflammation as well as a rapid cytoprotective effect with as a result a proteome reprograming of the host hepatocytes. The mode of action of GStemHep relie on the alleviation of inhibitory factors of liver regeneration, an increase in proliferation-promoting factors and a decrease in liver inflammation. We generated cryopreserved and current good manufacturing practice-compliant human pluripotent stem cell-derived immature hepatic progenitors that were highly effective in treating acute liver failure through rapid paracrine effects reprogramming endogenous hepatocytes. This is also the first report highlighting that human allogeneic cells could be used as cryopreserved cells and in the absence of immunosuppression for human PSC-based regenerative medicine for acute liver failure.
Sections du résumé
BACKGROUND
BACKGROUND
Liver transplantation remains the only curative treatment for end-stage liver diseases. Unfortunately, there is a drastic organ donor shortage. Hepatocyte transplantation emerged as a viable alternative to liver transplantation. Considering their unique expansion capabilities and their potency to be driven toward a chosen cell fate, pluripotent stem cells are extensively studied as an unlimited cell source of hepatocytes for cell therapy. It has been previously shown that freshly prepared hepatocyte-like cells can cure mice from acute and chronic liver failure and restore liver function.
METHODS
METHODS
Human PSC-derived immature hepatic progenitors (GStemHep) were generated using a new protocol with current good manufacturing practice compliant conditions from PSC amplification and hepatic differentiation to cell cryopreservation. The therapeutic potential of these cryopreserved cells was assessed in two clinically relevant models of acute liver failure, and the mode of action was studied by several analytical methods, including unbiased proteomic analyses.
RESULTS
RESULTS
GStemHep cells present an immature hepatic phenotype (alpha-fetoprotein positive, albumin negative), secrete hepatocyte growth factor and do not express major histocompatibility complex. A single dose of thawed GStemHep rescue mice from sudden death caused by acetaminophen and thioacetamide-induced acute liver failure, both in immunodeficient and immunocompetent animals in the absence of immunosuppression. Therapeutic biological effects were observed as soon as 3 h post-cell transplantation with a reduction in serum transaminases and in liver necrosis. The swiftness of the therapeutic effect suggests a paracrine mechanism of action of GStemHep leading to a rapid reduction of inflammation as well as a rapid cytoprotective effect with as a result a proteome reprograming of the host hepatocytes. The mode of action of GStemHep relie on the alleviation of inhibitory factors of liver regeneration, an increase in proliferation-promoting factors and a decrease in liver inflammation.
CONCLUSIONS
CONCLUSIONS
We generated cryopreserved and current good manufacturing practice-compliant human pluripotent stem cell-derived immature hepatic progenitors that were highly effective in treating acute liver failure through rapid paracrine effects reprogramming endogenous hepatocytes. This is also the first report highlighting that human allogeneic cells could be used as cryopreserved cells and in the absence of immunosuppression for human PSC-based regenerative medicine for acute liver failure.
Identifiants
pubmed: 38475825
doi: 10.1186/s13287-024-03673-9
pii: 10.1186/s13287-024-03673-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
71Informations de copyright
© 2024. The Author(s).
Références
Lefkowitch JH. The pathology of acute liver failure. Adv Anat Pathol. 2016. https://doi.org/10.1097/PAP.0000000000000112 .
doi: 10.1097/PAP.0000000000000112
Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet. 2010;376:190–201.
doi: 10.1016/S0140-6736(10)60274-7
Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41:1179–97.
doi: 10.1002/hep.20703
Hernández Vallejo G, Jiménez Romero C, de Vicente JC. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol. 2005;56:87–99.
doi: 10.1016/j.critrevonc.2004.12.011
Dhawan A, Puppi J, Hughes RD, Mitry RR. Human hepatocyte transplantation: current experience and future challenges. Nat Rev Gastroenterol Hepatol. 2010;7:288–98.
doi: 10.1038/nrgastro.2010.44
Hansel MC, Gramignoli R, Skvorak KJ, Dorko K, Marongiu F, Blake W, et al. The history and use of human hepatocytes for the treatment of liver diseases: the first 100 patients. Curr Protoc Toxicol. 2014;2014:14.12.1-14.12.23.
Dhawan A. Clinical human hepatocyte transplantation: current status and challenges. Liver Transpl. 2015;21:S39-44.
doi: 10.1002/lt.24226
Lee CA, Sinha S, Fitzpatrick E, Dhawan A. Hepatocyte transplantation and advancements in alternative cell sources for liver-based regenerative medicine. J Mol Med. 2018;91:469–81.
doi: 10.1007/s00109-018-1638-5
Iansante V, Mitry RR, Filippi C, Fitzpatrick E, Dhawan A. Human hepatocyte transplantation for liver disease: current status and future perspectives. Pediatr Res. 2018;83:232–40.
doi: 10.1038/pr.2017.284
Huch M, Gehart H, van Boxtel R, Hamer K, Blokzijl F, Verstegen MMA, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell. 2015;160:299–312.
doi: 10.1016/j.cell.2014.11.050
Hu H, Gehart H, Artegiani B, LÖpez-Iglesias C, Dekkers F, Basak O, et al. Long-term expansion of functional mouse and human hepatocytes as 3D organoids. Cell. 2018;175:1591-1606.e19.
doi: 10.1016/j.cell.2018.11.013
Garnier D, Li R, Delbos F, Fourrier A, Collet C, Guguen-Guillouzo C, et al. Expansion of human primary hepatocytes in vitro through their amplification as liver progenitors in a 3D organoid system. Sci Rep. 2018;8:8222.
doi: 10.1038/s41598-018-26584-1
Blackford SJI, Ng SS, Segal JM, King AJF, Austin AL, Kent D, et al. Validation of current good manufacturing practice compliant human pluripotent stem cell-derived hepatocytes for cell-based therapy. Stem Cells Transl Med. 2019;8:124–37.
doi: 10.1002/sctm.18-0084
Rashidi H, Luu NT, Alwahsh SM, Ginai M, Alhaque S, Dong H, et al. 3D human liver tissue from pluripotent stem cells displays stable phenotype in vitro and supports compromised liver function in vivo. Arch Toxicol. 2018;92:3117–29.
doi: 10.1007/s00204-018-2280-2
Schwartz RE, Fleming HE, Khetani SR, Bhatia SN. Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv. 2014;32:504–13.
doi: 10.1016/j.biotechadv.2014.01.003
Luce E, Messina A, Duclos-Vallée J-C, Dubart-Kupperschmitt A. Advanced techniques and awaited clinical applications for human pluripotent stem cell differentiation into hepatocytes. Hepatology. 2021. https://doi.org/10.1002/hep.31705 .
doi: 10.1002/hep.31705
Hannan NRF, Segeritz C-P, Touboul T, Vallier L. Production of hepatocyte like cells from human pluripotent stem cells. Nat Protoc. 2013;8:430–7.
doi: 10.1038/nprot.2012.153
Pettinato G, Lehoux S, Ramanathan R, Salem MM, He LX, Muse O, et al. Generation of fully functional hepatocyte-like organoids from human induced pluripotent stem cells mixed with Endothelial Cells. Sci Rep. 2019;9:8920.
doi: 10.1038/s41598-019-45514-3
Chen S, Wang J, Ren H, Liu Y, Xiang C, Li C, et al. Hepatic spheroids derived from human induced pluripotent stem cells in bio-artificial liver rescue porcine acute liver failure. Cell Res. 2020;30:95–7.
doi: 10.1038/s41422-019-0261-5
Tolosa L, Caron J, Hannoun Z, Antoni M, López S, Burks D, et al. Transplantation of hESC-derived hepatocytes protects mice from liver injury. Stem Cell Res Ther. 2015;6:1–17.
doi: 10.1186/s13287-015-0227-6
Pettinato G, Ramanathan R, Fisher RA, Mangino MJ, Zhang N, Wen X. Scalable differentiation of human iPSCs in a multicellular spheroid-based 3D culture into hepatocyte-like cells through direct Wnt/β-catenin pathway inhibition. Sci Rep. 2016;6:32888.
doi: 10.1038/srep32888
Nagamoto Y, Takayama K, Ohashi K, Okamoto R, Sakurai F, Tachibana M, et al. Transplantation of a human iPSC-derived hepatocyte sheet increases survival in mice with acute liver failure. J Hepatol. 2016. https://doi.org/10.1016/j.jhep.2016.01.004 .
doi: 10.1016/j.jhep.2016.01.004
Stéphenne X, Najimi M, Ngoc DK, Smets F, Hue L, Guigas B, et al. Cryopreservation of human hepatocytes alters the mitochondrial respiratory chain complex 1. Cell Transplant. 2007;16:409–19.
doi: 10.3727/000000007783464821
Terry C, Dhawan A, Mitry RR, Lehec SC, Hughes RD. Optimization of the cryopreservation and thawing protocol for human hepatocytes for use in cell transplantation. Liver Transplant. 2010;16:229–37.
doi: 10.1002/lt.21983
Fourrier A, Delbos F, Menoret S, Collet C, Thi Thuy LT, Myara A, et al. Regenerative cell therapy for the treatment of hyperbilirubinemic Gunn rats with fresh and frozen human induced pluripotent stem cells-derived hepatic stem cells. Xenotransplantation. 2020;27:e12544.
doi: 10.1111/xen.12544
Graffmann N, Scherer B, Adjaye J. In vitro differentiation of pluripotent stem cells into hepatocyte like cells—basic principles and current progress. Stem Cell Res. 2022. https://doi.org/10.1016/j.scr.2022.102763 .
doi: 10.1016/j.scr.2022.102763
Olszewski WL, Interewicz B, Durlik M, Rudowska A, Mecner B. Early loss of transplanted autologous hepatocytes-lysis by leukocytes in vivo and in vitro. Transplant Proc. 2001;33:651–3.
doi: 10.1016/S0041-1345(00)02185-0
Han B, Lu Y, Meng B, Qu B. Cellular loss after allogenic hepatocyte transplantation. Transplantation. 2009;87:1–5.
doi: 10.1097/TP.0b013e3181919212
Allen KJ, Mifsud NA, Williamson R, Bertolino P, Hardikar W. Cell-mediated rejection results in allograft loss after liver cell transplantation. Liver Transpl. 2008;14:688–94.
doi: 10.1002/lt.21443
Crook JM, Peura TT, Kravets L, Bosman AG, Buzzard JJ, Horne R, et al. The generation of six clinical-grade human embryonic stem cell lines. Cell Stem Cell. 2007;1:490–4.
doi: 10.1016/j.stem.2007.10.004
Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes [Internet]. Nucleic Acids Res. 2000. Available from: http://www.genome.ad.jp/kegg/
Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, Ebert D, et al. The gene ontology knowledgebase in 2023. In Baryshnikova A (ed) Genetics [Internet]. 2023;224. Available from: https://academic.oup.com/genetics/article/doi/ https://doi.org/10.1093/genetics/iyad031/7068118
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–13.
doi: 10.1093/nar/gky1131
Barbier L, Ferhat M, Salamé E, Robin A, Herbelin A, Gombert JM, et al. Interleukin-1 family cytokines: keystones in liver inflammatory diseases. Front Immunol. 2019;10:2014.
doi: 10.3389/fimmu.2019.02014
Saiman Y, Friedman SL. The role of chemokines in acute liver injury. Front Physiol. 2012. https://doi.org/10.3389/fphys.2012.00213 .
doi: 10.3389/fphys.2012.00213
Chen Y, Li Y, Wang X, Zhang W, Sauer V, Chang CJ, et al. Amelioration of hyperbilirubinemia in gunn rats after transplantation of human induced pluripotent stem cell-derived hepatocytes. Stem Cell Rep. 2015;5:22–30.
doi: 10.1016/j.stemcr.2015.04.017
Takebe T, Sekine K, Kimura M, Yoshizawa E, Ayano S, Koido M, et al. Massive and reproducible production of liver buds entirely from human pluripotent stem cells. Cell Rep. 2017;21:2661–70.
doi: 10.1016/j.celrep.2017.11.005
Wang Y, Zheng Q, Sun Z, Wang C, Cen J, Zhang X, et al. Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes. Cell Stem Cell. 2023;30:617-631.e8.
doi: 10.1016/j.stem.2023.03.013
Shi XL, Gao Y, Yan Y, Ma H, Sun L, Huang P, et al. Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes. Cell Res. 2016;26:206–16.
doi: 10.1038/cr.2016.6
Vosough M, Omidinia E, Kadivar M, Shokrgozar MA, Pournasr B, Aghdami N, et al. Generation of functional hepatocyte-like cells from human pluripotent stem cells in a scalable suspension culture. Stem Cells Dev. 2013;22:2693–705.
doi: 10.1089/scd.2013.0088
Liu H, Kim Y, Sharkis S, Marchionni L, Jang YY. In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci Transl Med. 2011. https://doi.org/10.1126/scitranslmed.3002376 .
doi: 10.1126/scitranslmed.3002376
Asgari S, Moslem M, Bagheri-Lankarani K, Pournasr B, Miryounesi M, Baharvand H. Differentiation and transplantation of human induced pluripotent stem cell-derived hepatocyte-like cells. Stem Cell Rev Rep. 2013;9:493–504.
doi: 10.1007/s12015-011-9330-y
Takayama K, Akita N, Mimura N, Akahira R, Taniguchi Y, Ikeda M, et al. Generation of safe and therapeutically effective human induced pluripotent stem cell-derived hepatocyte-like cells for regenerative medicine. Hepatol Commun. 2017;1:1058–69.
doi: 10.1002/hep4.1111
Jitraruch S, Dhawan A, Hughes RD, Filippi C, Lehec SC, Glover L, et al. Cryopreservation of hepatocyte microbeads for clinical transplantation. Cell Transplant. 2017;26:1341–54.
doi: 10.1177/0963689717720050
Kusunoki H, Taniyama Y, Otsu R, Rakugi H, Morishita R. Anti-inflammatory effects of hepatocyte growth factor on the vicious cycle of macrophages and adipocytes. Hypertens Res. 2014;37:500–6.
doi: 10.1038/hr.2014.41
Coudriet GM, He J, Trucco M, Mars WM, Piganelli JD. Hepatocyte growth factor modulates interleukin-6 production in bone marrow derived macrophages: Implications for inflammatory mediated diseases. PLoS One. 2010;5:e15384.
doi: 10.1371/journal.pone.0015384
Wang P, Cui Y, Wang J, Liu D, Tian Y, Liu K, et al. Mesenchymal stem cells protect against acetaminophen hepatotoxicity by secreting regenerative cytokine hepatocyte growth factor. Stem Cell Res Ther. 2022;13:1–14.
Michalopoulos GK. Liver regeneration. J Cell Physiol. 2007;213:286–300.
doi: 10.1002/jcp.21172
Wu Z, Han M, Chen T, Yan W, Ning Q. Acute liver failure: mechanisms of immune-mediated liver injury. Liver Int. 2010;30:782–94.
doi: 10.1111/j.1478-3231.2010.02262.x
Roth K, Strickland J, Gonzalez-Pons R, Pant A, Yen T, Freeborn R, et al. Interleukin-6 drives key pathologic outcomes in experimental acetaminophen-induced liver failure. BioRxiV. 2021
Coelho AM, Queiroz IF, Perucci LO, de Souza MO, Lima WG, Talvani A, et al. Piperine as therapeutic agent in paracetamol-induced hepatotoxicity in mice. Pharmaceutics. 2022;14:1800.
doi: 10.3390/pharmaceutics14091800
Chowdhury A, Lu J, Zhang R, Nabila J, Gao H, Wan Z, et al. Mangiferin ameliorates acetaminophen-induced hepatotoxicity through APAP-Cys and JNK modulation. Biomed Pharmacother. 2019;117:109097.
doi: 10.1016/j.biopha.2019.109097
Kato T, Ito Y, Hosono K, Suzuki T, Tamaki H, Minamino T, et al. Vascular endothelial growth factor receptor-1 signaling promotes liver repair through restoration of liver microvasculature after acetaminophen hepatotoxicity. Toxicol Sci. 2011;120:218–29.
doi: 10.1093/toxsci/kfq366
Papastefanou VP, Bozas E, Mykoniatis MG, Grypioti A, Garyfallidis S, Bartsocas CS, et al. VEGF isoforms and receptors expression throughout acute acetaminophen-induced liver injury and regeneration. Arch Toxicol. 2007;81:729–41.
doi: 10.1007/s00204-007-0201-x
Donahower B, Mccullough SS, Kurten R, Lamps LW, Simpson P, Hinson JA, et al. Vascular endothelial growth factor and hepatocyte regeneration in acetaminophen toxicity vascular endothelial growth factor and hepatocyte regenera-tion in acetaminophen toxicity. Am J Physiol Gastrointest Liver Physiol. 2006;291:102–9.
doi: 10.1152/ajpgi.00575.2005
Lehmann K, Tschuor C, Rickenbacher A, Jang JH, Oberkofler CE, Tschopp O, et al. Liver failure after extended hepatectomy in mice is mediated by a p21-dependent barrier to liver regeneration. Gastroenterology. 2012;143:1609.
doi: 10.1053/j.gastro.2012.08.043
Bhushan B, Walesky C, Manley M, Gallagher T, Borude P, Edwards G, et al. Pro-regenerative signaling after acetaminophen-induced acute liver injury in mice identified using a novel incremental dose model. Am J Pathol. 2014;184:3013–25.
doi: 10.1016/j.ajpath.2014.07.019
Ganey PE, Luyendyk JP, Newport SW, Eagle TM, Maddox JF, Mackman N, et al. Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice. Hepatology. 2007;46:1177–86.
doi: 10.1002/hep.21779
Shan Z, Li L, Lynn Atkins C, Wang M, Wen Y, Moreno NF, et al. Chitinase 3-like-1 contributes to acetaminophen-induced liver injury by promoting hepatic platelet recruitment. Southwestern Med School. 2021
Bird TG, Muller M, Boulter L, Vincent DF, Ridgway RA, Lopez-Guadamillas E, et al. TGFβ inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence. Sci Transl Med. 2018;10:eaan1230.
doi: 10.1126/scitranslmed.aan1230
Basu J, Assaf BT, Bertram TA, Rao M. Preclinical biosafety evaluation of cell-based therapies: emerging global paradigms. Toxicol Pathol. 2015;43:115–25.
doi: 10.1177/0192623314559104
Kusakawa S, Yasuda S, Kuroda T, Kawamata S, Sato Y. Ultra-sensitive detection of tumorigenic cellular impurities in human cell-processed therapeutic products by digital analysis of soft agar colony formation. Sci Rep. 2015;5:17892.
doi: 10.1038/srep17892
Perez-Riverol Y, Bai J, Bandla C, García-Seisdedos D, Hewapathirana S, Kamatchinathan S, et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022;50:D543–52.
doi: 10.1093/nar/gkab1038